$Chemomab Therapeutics (CMMB.US)$ Reuters· 2 mins ago
Chemomab Therapeutics Ltd - Treatment for up to 48 Weeks Was Well-Tolerated

$Chemomab Therapeutics (CMMB.US)$
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Thursday, 27th March at 8:30 am
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments
Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in continued improv...

$Chemomab Therapeutics (CMMB.US)$ On Track for Releasing Clinical Data from SPRING Trial Open Label Extension in First Quarter 2025

$Chemomab Therapeutics (CMMB.US)$ let it rip

$Chemomab Therapeutics (CMMB.US)$
The FDA's agreement to Chemomab's innovative Phase 3 trial design for nebokitug represents a groundbreaking development in PSC drug development. This is the first time the FDA has accepted clinical events as primary endpoints for PSC treatment approval, marking a paradigm shift from traditional approaches that relied heavily on surrogate markers and liver biopsies.
The streamlined approval pathway through a single Phase 3 trial has seve...

$Chemomab Therapeutics (CMMB.US)$
FDA Fast-Tracks Revolutionary PSC Drug: Single Phase 3 Trial Could Change Rare Disease Treatment

$Chemomab Therapeutics (CMMB.US)$ Reuters· 4 mins ago
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns With FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (Cm-101) in Primary Sclerosing Cholangitis

$Chemomab Therapeutics (CMMB.US)$
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Chemomab Therapeutics presented Phase 2 SPRING trial data for CM-101 in primary sclerosing cholangitis (PSC) at AASLD The Liver Meeting® 2024.
The trial, involving 76 patients, tested two doses (10 mg/kg and 20 mg/kg) administered every three weeks over 15 w...